Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) PIAS4 Antibodies:
anti-Human PIAS4 Antibodies:
anti-Rat (Rattus) PIAS4 Antibodies:
Go to our pre-filtered search.
Human Polyclonal PIAS4 Primary Antibody for ICC, IF - ABIN269501
Tong, Shen, Wang, Kan, Wang, Li, Wang, Yang, Guo: DNA ploidy cytometry testing for cervical cancer screening in China (DNACIC Trial): a prospective randomized, controlled trial. in Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Show all 6 Pubmed References
Human Polyclonal PIAS4 Primary Antibody for IF, WB - ABIN537320
Zoumpoulidou, Jones, Fernandez de Mattos, Francis, Fusi, Lee, Christian, Varshochi, Lam, Brosens: Convergence of interferon-gamma and progesterone signaling pathways in human endometrium: role of PIASy (protein inhibitor of activated signal transducer and activator of transcription-y). in Molecular endocrinology (Baltimore, Md.) 2004
Show all 3 Pubmed References
Human Polyclonal PIAS4 Primary Antibody for IHC (p), WB - ABIN388061
Imoto, Sugiyama, Muromoto, Sato, Yamamoto, Matsuda: Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3. in The Journal of biological chemistry 2003
Show all 5 Pubmed References
Human Polyclonal PIAS4 Primary Antibody for ICC, IF - ABIN441248
Alshareeda, Negm, Green, Nolan, Tighe, Albarakati, Sultana, Madhusudan, Ellis, Rakha: SUMOylation proteins in breast cancer. in Breast cancer research and treatment 2014
Cow (Bovine) Polyclonal PIAS4 Primary Antibody for WB - ABIN2777708
Zhang, Xu, Han, Wei, Shu: PIASy represses TRIF-induced ISRE and NF-kappaB activation but not apoptosis. in FEBS letters 2004
Show all 2 Pubmed References
Findings indicate that protein inhibitor of activated STAT 4 (PIAS4) mediated SIRT1 (show SIRT1 Antibodies) repression in response to nutrient surplus contributes to the pathogenesis of Nonalcoholic Steatohepatitis (NASH (show SAMSN1 Antibodies)).
new protein isoform encoded by KIAA0317, termed fibrosis-inducing E3 ligase 1 (FIEL1), which potently stimulates the TGFbeta (show TGFB1 Antibodies) signaling pathway through the site-specific ubiquitination of PIAS4.
PKA-induced SREBP1c (show SREBF1 Antibodies) sumoylation by PIASy.
the SUMO E3 ligase (show PIAS1 Antibodies) PIASy (also known as PIAS4) was induced by hypoxia and prevented Sp1 (show SP1 Antibodies) from binding to the SIRT1 (show SIRT1 Antibodies) promoter.
Piasy represses the synergistic activation of PITX2 (show PITX2 Antibodies) with interacting co-factors and Piasy represses Pias1 (show PIAS1 Antibodies) activation of PITX2 (show PITX2 Antibodies) transcriptional activity.
Protein inhibitor of activated STAT (show STAT1 Antibodies), PIASy regulates alpha-smooth muscle actin (show ACTG2 Antibodies) expression by interacting with E12 (show ELSPBP1 Antibodies) in mesangial cells.
PIASy negatively regulates both IFN transcription and IFN-stimulated gene expression through multiple mechanisms utilizing the function of different domains.
Studies define an important role of PIASy in hypoxia signaling through promoting HIF1alpha (show HIF1A Antibodies) SUMOylation.
PIASgamma as a transcriptional co-regulator of Nurr1 (show NR4A2 Antibodies) and suggest that this interaction may have a physiological role in regulating the expression of Nurr1 (show NR4A2 Antibodies) target genes.
Piasy(-/-) mice appear phenotypically normal, activation of STAT1 (show STAT1 Antibodies) is not significantly perturbed, and sumoylation patterns for SUMO-1 (show SUMO1 Antibodies) or SUMO-3 (show SUMO3 Antibodies) modification are similar in wild-type and knockout mice
post-translational modification of Nkx3.2 (show NKX3-2 Antibodies) employing HDAC9 (show HDAC9 Antibodies)-PIASy-RNF4 (show RNF4 Antibodies) axis plays a crucial role in controlling chondrocyte viability and hypertrophic maturation during skeletal development in vertebrates.
these findings provide evidence for the effects of PIAsxalpha (show PIAS2 Antibodies) and its mechanism on osteosarcoma progression, which offers novel insight into sumoylation and the cell cycle in osteosarcoma.
PIAS4 was identified as a candidate gene for abnormal head size in 13 patients with proximal 19p13.3 submicroscopic rearrangements .
Our data reveal a novel and dynamic role for PIAS4 in the cellular-mediated restriction of herpesviruses and establish a new functional role for the PIAS family of SUMO ligases in the intrinsic antiviral immune response to DNA virus infection.
PIAS4 activity are required for the AMPKalpha1 (show PRKAA1 Antibodies) SUMOylation and the inhibition of AMPKalpha1 (show PRKAA1 Antibodies) activity towards mTORC1 signalling.
PIAS4 (rs735842) and VEGFA (show VEGFA Antibodies) (rs699947) were the most statistically significant variants associated in hypoxia pathway analysis.
PIASgamma-dependent modification of tomosyn-1 (show STXBP5 Antibodies) with SUMO-2 (show SUMO2 Antibodies)/3 presents a novel mechanism to adapt secretory strength to the dynamic synaptic environment.
SUMOylation of RXRalpha (show RXRA Antibodies) is significantly enhanced through PIAS4-mediated activity.
High reactive oxygen speciesinduces oxidation and ubiquitin-mediated degradation of PIASgamma, thereby disrupting PIASgamma-IKKgamma (show IKBKG Antibodies) cross talk.
Data suggest that PIASy exhibits a SIM (show SIM2 Antibodies) (SUMO-interacting motif) in addition to the SIM (show SIM2 Antibodies) identified in homologous proteins in other species; both SIMs are located near C terminus of PIASy, and both are required for full ligase activity of PIASy; hydrophobic core residues of the new SIM (show SIM2 Antibodies) are essential in binding to SUMO-3 (show SUMO3 Antibodies). (PIASy = protein inhibitors of activated STAT (show STAT1 Antibodies) y; SUMO-3 (show SUMO3 Antibodies) = small ubiquitin-like modifier 3 (show SUMO3 Antibodies))
The Xenopus PIAS (show PIAS1 Antibodies) genes are expressed throughout early development and have overlapping and distinct expression patterns, with, for example, strong expression of PIAS4 in the neural and neural crest derivatives.
XPIASy functions as an essential negative regulator of the XSmad2 (show SMAD2 Antibodies) pathway to ensure proper mesoderm induction at the appropriate time and in the appropriate region.
Data show that the Rod/Zw10 (show ZW10 Antibodies) complex interacts with the first 47 residues of PIASy which are important for mitotic SUMOylation, and that depletion of Rod compromises the centromeric localization of PIASy and SUMO2 (show SUMO2 Antibodies)/3 in mitosis.
a PIAS4 homologue (zfPIAS4a) from the zebrafish model that shares many conserved structural hallmarks with the human and mammal PIAS4 proteins was successfully identified
Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway, the Wnt pathway and the steroid hormone signaling pathway. Involved in gene silencing. Promotes PARK7 sumoylation. In Wnt signaling, represses LEF1 and enhances TCF4 transcriptional activities through promoting their sumoylations.
protein inhibitor of activated STAT, 4
, protein inhibitor of activated STAT protein 4
, E3 SUMO-protein ligase PIAS4-like
, e3 SUMO-protein ligase PIAS4-like
, E3 SUMO-protein ligase PIAS4
, protein inhibitor of activated STAT PIASy
, protein inhibitor of activated STAT protein gamma
, protein inhibitor of activated STAT protein PIASy
, zinc finger, MIZ-type containing 6
, protein inhibitor of activated STAT 4